It is relatively resistant to radiation therapy and chemotherapy, although some cases respond to targeted therapies such as sunitinib, temsirolimus, bevacizumab, interferon alfa and sorafenib have improved the outlook for RCC.
It is relatively resistant to radiation therapy and chemotherapy. Some cases respond to targeted therapies such as sunitinib, temsirolimus, bevacizumab, interferon alfa. Sorafenib have improved the outlook for RCC.